InMode Ltd.

INMD

IL0011595993

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
17.69 ^USD	-1.28%		-10.61%	-20.46%

Apr. 12	Barclays Adjusts Price Target on InMode to $33 From $34, Maintains Overweight Rating	MT
Apr. 09	Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday	MT

InMode Ltd. Provides Revenue Guidance for the First Quarter Ended March 31, 2022

April 11, 2022 at 08:00 am EDT

InMode Ltd. provides revenue guidance for the first quarter ended March 31, 2022. The company expects, Revenue for the first quarter of 2022 in the range of $85.0 million to $85.5 million.

Latest news about InMode Ltd.

Barclays Adjusts Price Target on InMode to $33 From $34, Maintains Overweight Rating	Apr. 12	MT
Sector Update: Health Care Stocks Edge Higher Pre-Bell Tuesday	Apr. 09	MT
InMode Lowers Fiscal 2024 Revenue Forecast, Issues Fiscal Q1 Guidance	Apr. 09	MT
Inmode Ltd. Provides Revenue Guidance for the First Quarter of 2024	Apr. 09	CI
Glass Lewis Issues Shareholders Alert on InMode Ahead of Annual Meeting	Mar. 20	MT
InMode Seeks M&A	Mar. 13	CI
Transcript : InMode Ltd. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:05 PM	Mar. 13
Barclays Adjusts Price Target on InMode to $34 From $32, Maintains Overweight Rating	Feb. 15	MT
UBS Adjusts InMode Price Target to $26 From $24, Maintains Neutral Rating	Feb. 14	MT
InMode's Q4 Non-GAAP Earnings, Revenue Fall; 2024 Guidance Issued	Feb. 13	MT
Transcript : InMode Ltd., Q4 2023 Earnings Call, Feb 13, 2024	Feb. 13
Earnings Flash (INMD) INMODE Posts Q4 EPS $0.71, vs. Street Est of $0.67	Feb. 13	MT
InMode Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13	CI
InMode Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 13	CI
North American Morning Briefing : Stocks Seen -2-	Feb. 13	DJ
Barclays Trims Price Target on InMode to $32 From $33, Maintains Overweight Rating	Jan. 18	MT
InMode Ltd. Provides Revenue Guidance for the Fourth Quarter, Full Year of 2023 and for the Full Year of 2024	Jan. 16	CI
InMode Ltd. Revises Earnings Guidance for the Full Year 2023	Dec. 06	CI
UBS Downgrades InMode to Neutral From Buy, Cuts Price Target to $24 From $52	Nov. 03	MT
Transcript : InMode Ltd., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Earnings Flash (INMD) INMODE Reports Q3 EPS $0.61, vs. Street Est of $0.63	Nov. 02	MT
InMode Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
InMode Files Patent Infringement Complaint Against BTL Industries	23-10-13	MT
InMode Issues Q3 Non-GAAP Earnings, Revenue Expectations; 2023 Revenue Guidance Cut	23-10-12	MT
InMode Ltd. Revises Revenue Guidance for the Full Year 2023	23-10-12	CI

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women's health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-01 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for InMode Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

17.69 USD

Average target price

27.6 USD

Spread / Average Target

+56.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
INMODE LTD.	-20.46%	1.5B
THERMO FISHER SCIENTIFIC	+5.10%	213B
DANAHER CORPORATION	+3.60%	177B
INTUITIVE SURGICAL, INC.	+11.86%	134B
BOSTON SCIENTIFIC CORPORATION	+16.66%	99.13B
SIEMENS HEALTHINEERS AG	+0.19%	63.47B
EDWARDS LIFESCIENCES CORPORATION	+16.98%	53.69B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-4.51%	46.36B
AGILENT TECHNOLOGIES, INC.	+0.86%	41.09B
GE HEALTHCARE TECHNOLOGIES INC.	+11.39%	39.3B

Other Advanced Medical Equipment & Technology

InMode Ltd.

Equities

INMD

IL0011595993

Advanced Medical Equipment & Technology

InMode Ltd. Provides Revenue Guidance for the First Quarter Ended March 31, 2022

Latest news about InMode Ltd.

Chart InMode Ltd.

Company Profile

Income Statement Evolution

Ratings for InMode Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology